Leszek Lisowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4680573/publications.pdf

Version: 2024-02-01

218592 197736 2,599 52 26 49 citations h-index g-index papers 54 54 54 3556 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014, 506, 382-386.	13.7	376
2	Human <i>COL7A1</i> -corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Science Translational Medicine, 2014, 6, 264ra163.	5.8	194
3	Genome Editing of Isogenic Human Induced Pluripotent Stem Cells Recapitulates Long QT Phenotype for Drug Testing. Journal of the American College of Cardiology, 2014, 64, 451-459.	1.2	149
4	Bioengineered AAV Capsids with Combined High Human Liver Transduction InÂVivo and Unique Humoral Seroreactivity. Molecular Therapy, 2018, 26, 289-303.	3.7	130
5	A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nature Biotechnology, 2006, 24, 89-94.	9.4	114
6	Adeno-associated virus serotypes for gene therapeutics. Current Opinion in Pharmacology, 2015, 24, 59-67.	1.7	113
7	In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. Molecular Therapy, 2018, 26, 1818-1827.	3.7	111
8	Genome Editing of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells With Zinc Finger Nucleases for Cellular Imaging. Circulation Research, 2012, 111, 1494-1503.	2.0	99
9	An Atypical Parvovirus Drives Chronic Tubulointerstitial Nephropathy and Kidney Fibrosis. Cell, 2018, 175, 530-543.e24.	13.5	89
10	Identification of liver-specific enhancer $\hat{a} \in \text{``promoter activity in the 3} \hat{a} \in \text{''} 2$ untranslated region of the wild-type AAV2 genome. Nature Genetics, 2017, 49, 1267-1273.	9.4	78
11	Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nature Communications, 2017, 8, 2053.	5.8	78
12	Optogenetic approaches to vision restoration. Experimental Eye Research, 2019, 178, 15-26.	1.2	77
13	The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. Gastroenterology, 2021, 160, 1224-1239.e30.	0.6	76
14	High-Throughput <i>In Vitro</i> , <i>Ex Vivo,</i> and <i>In Vivo</i> Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction. Human Gene Therapy, 2020, 31, 575-589.	1.4	65
15	Somatic Correction of Junctional Epidermolysis Bullosa by a Highly Recombinogenic AAV Variant. Molecular Therapy, 2014, 22, 725-733.	3.7	60
16	Age-Related Seroprevalence of Antibodies Against AAV-LKO3 in a UK Population Cohort. Human Gene Therapy, 2019, 30, 79-87.	1.4	51
17	Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in β-thalassemic mice. Blood, 2007, 110, 4175-4178.	0.6	50
18	Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editing. Nature Communications, 2020, 11, 4871.	5.8	46

#	Article	IF	CITATIONS
19	Restoring the natural tropism of AAV2 vectors for human liver. Science Translational Medicine, 2020, 12, .	5.8	41
20	Erythroid-specific Human Factor IX Delivery From In Vivo Selected Hematopoietic Stem Cells Following Nonmyeloablative Conditioning in Hemophilia B Mice. Molecular Therapy, 2008, 16, 1745-1752.	3.7	39
21	Progress Toward the Genetic Treatment of the \hat{I}^2 -Thalassemias. Annals of the New York Academy of Sciences, 2005, 1054, 78-91.	1.8	36
22	AAV Vectors Containing rDNA Homology Display Increased Chromosomal Integration and Transgene Persistence. Molecular Therapy, 2012, 20, 1902-1911.	3.7	36
23	Current status of globin gene therapy for the treatment of βâ€ŧhalassaemia. British Journal of Haematology, 2008, 141, 335-345.	1.2	35
24	rAAV-Mediated Tumorigenesis: Still Unresolved After an AAV Assault. Molecular Therapy, 2012, 20, 2014-2017.	3.7	33
25	A User's Guide to the Inverted Terminal Repeats of Adeno-Associated Virus. Human Gene Therapy Methods, 2019, 30, 206-213.	2.1	33
26	RNA interference–induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice. Nature Medicine, 2016, 22, 557-562.	15.2	32
27	Attenuation of Heparan Sulfate Proteoglycan Binding Enhances InÂVivo Transduction of Human Primary Hepatocytes with AAV2. Molecular Therapy - Methods and Clinical Development, 2020, 17, 1139-1154.	1.8	29
28	Ribosomal DNA Integrating rAAV-rDNA Vectors Allow for Stable Transgene Expression. Molecular Therapy, 2012, 20, 1912-1923.	3.7	27
29	A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization. Angiogenesis, 2021, 24, 97-110.	3.7	23
30	Codon-Optimization of Wild-Type Adeno-Associated Virus Capsid Sequences Enhances DNA Family Shuffling while Conserving Functionality. Molecular Therapy - Methods and Clinical Development, 2019, 12, 71-84.	1.8	22
31	Bioengineered Viral Platform for Intramuscular Passive Vaccine Delivery to Human Skeletal Muscle. Molecular Therapy - Methods and Clinical Development, 2018, 10, 144-155.	1.8	21
32	Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Molecular Therapy - Methods and Clinical Development, 2021, 23, 135-146.	1.8	21
33	Novel human liver-tropic AAV variants define transferable domains that markedly enhance the human tropism of AAV7 and AAV8. Molecular Therapy - Methods and Clinical Development, 2022, 24, 88-101.	1.8	21
34	Efficient inÂvivo editing of OTC-deficient patient-derived primary human hepatocytes. JHEP Reports, 2020, 2, 100065.	2.6	18
35	AAV-p40 Bioengineering Platform for Variant Selection Based on Transgene Expression. Human Gene Therapy, 2022, 33, 664-682.	1.4	16
36	Targeting Adeno-Associated Virus Vectors for Local Delivery to Fractures and Systemic Delivery to the Skeleton. Molecular Therapy - Methods and Clinical Development, 2019, 15, 101-111.	1.8	15

#	Article	IF	CITATIONS
37	Neurological Disorders Associated with WWOX Germline Mutations—A Comprehensive Overview. Cells, 2021, 10, 824.	1.8	15
38	Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids. Molecular Therapy - Methods and Clinical Development, 2021, 21, 607-620.	1.8	13
39	The intersection of vector biology, gene therapy, and hemophilia. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12586.	1.0	13
40	Transient <i>In Vivo</i> \hat{I}^2 -Globin Production After Lentiviral Gene Transfer to Hematopoietic Stem Cells in the Nonhuman Primate. Human Gene Therapy, 2009, 20, 563-572.	1.4	12
41	Supplying Clotting Factors From Hematopoietic Stem Cell–derived Erythroid and Megakaryocytic Lineage Cells. Molecular Therapy, 2009, 17, 1994-1999.	3.7	12
42	The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. Nucleic Acids Research, 2013, 41, 3688-3698.	6.5	12
43	Systemic AAV8-mediated delivery of a functional copy of muscle glycogen phosphorylase (Pygm) ameliorates disease in a murine model of McArdle disease. Human Molecular Genetics, 2020, 29, 20-30.	1.4	12
44	The self-peptide repertoire plays a critical role in transplant tolerance induction. Journal of Clinical Investigation, 2021, 131, .	3.9	10
45	Globin gene transfer: a paradigm for transgene regulation and vector safety. Gene Therapy and Regulation, 2003, 2, 149-175.	0.3	9
46	Potential Applications for Targeted GeneÂTherapy to Protect Against Anthracycline Cardiotoxicity. JACC: CardioOncology, 2021, 3, 650-662.	1.7	9
47	Second Generation Codon Optimized Minicircle (CoMiC) for Nonviral Reprogramming of Human Adult Fibroblasts. Methods in Molecular Biology, 2014, 1181, 1-13.	0.4	7
48	Globin gene transfer for treatment of the \hat{I}^2 -thalassemias and sickle cell disease. Best Practice and Research in Clinical Haematology, 2004, 17, 517-534.	0.7	7
49	Comparison of transduction efficiency among various lentiviruses containing GFP reporter in bone marrow hematopoietic stem cell transplantation. Experimental Hematology, 2013, 41, 934-943.	0.2	5
50	Directed Evolution of Adeno-Associated Virus Vectors in Human Cardiomyocytes for Cardiac Gene Therapy. Heart Lung and Circulation, 2018, 27, 1270-1273.	0.2	4
51	Selection of a novel AAV2/TNFAIP3 vector for local suppression of islet xenograft inflammation. Xenotransplantation, 2021, 28, e12669.	1.6	4
52	737. RNAi Induced Hepatotoxicity Results from a Functional Depletion of the First Synthesized Isoform of miR-122. Molecular Therapy, 2016, 24, S290-S291.	3.7	0